Singapore markets closed

NVO250117P00043750

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.80000.0000 (0.00%)
As of 12:00AM EDT. Market open.
Full screen
Previous close0.8000
OpenN/A
BidN/A
AskN/A
StrikeN/A
Expiry date2025-01-17
Day's range0.8000 - 0.8000
Contract rangeN/A
VolumeN/A
Open interestN/A
  • PR Newswire

    Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®

    Novo Nordisk today launched The Power of Wegovy®, a new national campaign. The campaign aims to educate on the clinical data of Wegovy® (semaglutide) 2.4 mg injection and reflect the collective empowerment people living with obesity can feel when they don't have to manage their weight alone.

  • The Telegraph

    The ‘hardcore’ scientists shifting the dial on obesity

    When Nadeem Sarwar got a call asking him to work on stopping people becoming obese, he was “quite confused”.

  • Yahoo Finance Video

    Ro CEO on GLP-1 drug shortage: US healthcare is '1 of 1'

    GLP-1 medication supply constraints have left many patients grappling with the challenge of accessing these highly sought-after drugs. Ro CEO Zach Reitano joins Asking for a Trend to shed light on how his company aims to make supply information more readily available to patients in need. Reitano underscores Ro's core mission of "building goal-oriented healthcare" tailored to the individual needs of its patients. Recently, the company has been dedicating its efforts to addressing obesity, but they have also recognized "a massive shortage" in the availability of GLP-1 drugs. Consequently, Ro has been proactively "building products and services to help patients navigate and manage through these supply challenges." Reitano characterizes the current US healthcare landscape as "one of one," noting that "never before in healthcare has the majority of the US population been eligible for a drug." This situation has led to patients and providers "desperately" wanting access to these therapies, resulting in severe supply-demand dynamics, a challenge Reitano believes could persist for years to come. Reitano explains Ro's goal is to "crowdsource" supply information with its tracker, streamlining the process of accessing these drugs for both patients and healthcare providers. For more expert insight and the latest market action, click here to watch this full episode of Asking for a Trend. This post was written by Angel Smith